The purpose of this Expanded Access Program (EAP) is to allow patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the human epidermal growth factor receptor 2 (HER2) gene, which have no other therapeutic option, to receive sevabertinib (BAY2927088).

Expanded Access to Provide BAY2927088 for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation

Details and patient eligibility

Trial contacts and locations